Summary
Cencora, Inc. (COR) has announced a significant strategic acquisition, agreeing to purchase the majority of the outstanding equity interests it doesn't currently own in OneOncology. This move is expected to cost approximately $3.6 billion for the equity, plus the retirement of $1.3 billion in existing corporate debt, totaling $5.0 billion in cash consideration. The acquisition aims to bolster Cencora's position in the oncology market by integrating OneOncology's physician-led national platform, which supports independent medical specialty practices. OneOncology's affiliated practices and management will retain a minority stake. The transaction is slated to be funded through new debt financing, with $4.5 billion in bridge financing commitments secured, and is contingent upon customary closing conditions, including regulatory approvals.
Key Highlights
- 1Cencora (COR) to acquire majority equity interests in OneOncology for approximately $3.6 billion.
- 2Total transaction cost, including $1.3 billion debt retirement, amounts to $5.0 billion in cash.
- 3OneOncology's existing practices and management will retain a minority interest.
- 4The acquisition is financed through new debt, with $4.5 billion in bridge financing commitments obtained.
- 5Transaction is subject to customary closing conditions and regulatory approvals.
- 6The press release was issued on December 15, 2025, and the agreement was entered into on December 12, 2025.
- 7This move aims to strengthen Cencora's presence in the oncology sector through OneOncology's independent practice platform.